DocGo Inc.
No SEC Form 4 filings for $DCGO in the last 30 days.
See all $DCGO insider activity →DocGo (DCGO) shares rose 2.4% in after-hours to $0.727 after its Q2 2026 earnings release and a 5:00 p.m. ET management call. Analysts expected a 15-cent per-share loss versus a 21-cent loss a year earlier. DocGo also sought a short SEC 10-Q filing extension and reiterated no major operating changes, with prior FY2026 sales guidance raised and a $26M buyback extended.
DocGo Inc. (DCGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-2.1 2 exhibit2mergeragreement.htm EX-2.1 Document EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of August 16, 2026 among DocGo Inc., Ambulnz Holdings, LLC, HH Merger Sub, LLC, Hicuity Health, Inc., Concord Innovation Fund II, LP, and Concord Innovation Fund II, LP, a
DocGo Inc. (DCGO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. dcgo-20260616 0001822359 FALSE 0001822359 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie
Over the past 7 days, alphai's AI scored 2 news stories mentioning DCGO (DocGo Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent DCGO coverage spans financial news, earnings and corporate actions.
After-hours strength appears driven by an earnings beat versus a modest loss consensus and supportive prior guidance plus an extended buyback program.
The filing signals DocGo is entering a merger process, which typically increases event-driven volatility and shifts focus to deal terms, closing conditions, and any earnout or post-closing adjustments.
The 8-K discloses finalized shareholder votes on corporate governance actions, notably a reverse stock split authorization, which can affect share count, liquidity, and near-term trading dynamics.
Despite a Q4 revenue beat and increased 2026 revenue guidance, the analyst has lowered the price target from $4.00 to $2.50, indicating potential downside risk. The stock trades at approximately $0.79, suggesting limited immediate upside based on the new target. The company faces execution risks due to EPS miss, revenue decline, and weak margins.
The investigation by Halper Sadeh LLC into DocGo Inc. indicates potential governance concerns, which may exert downward pressure on the stock.
alphai scores every news story that mentions DCGO with an AI model for sentiment and relevance, and aggregates insider trades from DocGo Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DocGo (DCGO) shares rose 2.4% in after-hours to $0.727 after its Q2 2026 earnings release and a 5:00 p.m. ET management call. Analysts expected a 15-cent per-share loss versus a 21-cent loss a year earlier. DocGo also sought a short SEC 10-Q filing extension and reiterated no major operating changes, with prior FY2026 sales guidance raised and a $26M buyback extended.
5 min readDocGo Inc. (DCGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-2.1 2 exhibit2mergeragreement.htm EX-2.1 Document EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of August 16, 2026 among DocGo Inc., Ambulnz Holdings, LLC, HH Merger Sub, LLC, Hicuity Health, Inc., Concord Innovation Fund II, LP, and Concord Innovation Fund II, LP, a
6 min readDocGo Inc. (DCGO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. dcgo-20260616 0001822359 FALSE 0001822359 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie
3 min readStifel Nicolaus has lowered its price target for DocGo (NASDAQ:DCGO) to $2.50 from $4.00, while maintaining a "buy" rating, indicating a potential upside of 218%. Despite a Q4 revenue beat and raised 2026 revenue guidance of $290M–$310M, the company faces significant execution risk due to a large EPS miss, year-over-year revenue decline, and weak margins, with the stock currently trading around $0.79. DocGo is exploring strategic alternatives to push towards profitability.
4 min readHalper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DocGo Inc. (NASDAQ: DCGO) breached their fiduciary duties to long-term shareholders. The firm encourages current DocGo shareholders to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or the return of funds to the company. The investigation aims to enhance shareholder value through improved company policies and oversight.
2 min readMotion Acquisition (DCGO) delivered earnings and revenue surprises of -22.22% and +0.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min readNEW YORK CITY and NEW ORLEANS, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ( "KSF" ) , announces that KSF continues its investigation into DocGo Inc. DCGO.
2 min readSAN DIEGO, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: General Motors Company GM, DocGo Inc. DCGO, The Estée Lauder Companies Inc. EL, and Axsome Therapeutics, Inc. AXSM.
3 min readMotion Acquisition (DCGO) delivered earnings and revenue surprises of -83.33% and +4.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readSAN DIEGO, June 04, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: General Motors Company GM, DocGo Inc. DCGO, The Estée Lauder Companies Inc. EL, and Axsome Therapeutics, Inc. AXSM.
2 min read
